Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study
Open accessAbstract
BACKGROUND: Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission. AIMS: Duloxetine, an inhibitor of serotonin and noradrenaline reuptake that is licensed in Europe, the USA and elsewhere for the treatment of depressive episodes, was evaluated with regard to its efficacy, safety and tolerability in the prevention of relapse of MDD. METHOD: Adult out-patients with MDD received duloxetine (60 mg daily) for 12 weeks (n=533). Patients who responded to the drug were then randomised to duloxetine(60 mg daily)(n=136) or or placebo placebo (n=142) for 26 weeks. The primary measure of efficacy was time to relapse. RESULTS: Patients who received duloxetine (60 mg daily) experienced significantly longer times to relapse of MDD, and better efficacy, global well-being, and quality-of-life outcomes compared with patients who received placebo. It should be noted that adverse events which occur in discontinuation may mimic some signs of depressive relapse, and were not specifically elicited in this study. CONCLUSIONS: Duloxetine (60 mg daily) is effective in the prevention of relapse of MDD during continuation treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The results of the first levomilnacipran ER relapse-prevention study are inconsistent with relapse-prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%).
“the results of the first levomilnacipran ER relapse‐prevention study are inconsistent with relapse‐prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%; Perahia et al., 2006; Rickels et al., 2010; Simon, Aguiar, Kunz, & Lei, 2004).”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Perahia et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · see citing works
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801 · see citing works
The Visual Analog Scale in the Immediate Postoperative Period
DeLoach, L. J., Higgins, M. S., Caplan, A. B., & Stiff, J. L. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199801000-00020 · Cited by 727 · see citing works
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 716 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · see citing works
(1987) · PubMed · Cited by 439 · see citing works
Melfi, C. A., Chawla, A. J., Croghan, T. W., Hanna, M. P., Kennedy, S., & Sredl, K. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1128 · Cited by 409 · see citing works
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · see citing works
Cost of depression among adults in England in 2000
Thomas, C. M., & Morris, S. (2003) · The British Journal of Psychiatry · doi:10.1192/bjp.183.6.514 · Cited by 282 · see citing works
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Detke, M. J., Lu, Y., GOLDSTEIN, D. J., McNamara, R. K., & Demitrack, M. A. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00060-2 · Cited by 278 · see citing works
Duloxetine for the Treatment of Major Depressive Disorder
Nemeroff, C. B., Schatzberg, A. F., PhD, Schatzberg, A. F., MD, GOLDSTEIN, D. J., Trân, P. V., PhD, Detke, M. J., Lu, Y., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4207 · Cited by 177 · see citing works
Montgomery, S., Rasmussen, J., & Tanghøj, P. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00008 · Cited by 165 · see citing works
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Drug Information Journal · doi:10.1177/009286150103500418 · Cited by 160 · see citing works
The economic burden of depression with painful symptoms.
Greenberg, P. E., Leong, S. A., Birnbaum, H. G., & Robinson, R. L. (2003) · PubMed · Cited by 122 · see citing works
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121 · see citing works
Somatic Symptoms, Depression, and Antidepressant Treatment
Fava, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0406 · Cited by 90 · see citing works
Clinical importance of long-term antidepressant treatment
Hirschfeld, R. M. A. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.42.s4 · Cited by 89 · see citing works
Challenges in preventing relapse in major depression
Segal, Z. V., Pearson, J. L., & Thase, M. E. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00112-x · Cited by 87 · see citing works
McKenna, S. P., & Hunt, S. M. (1992) · Health Policy · doi:10.1016/0168-8510(92)90005-v · Cited by 78 · see citing works
Treatment Approaches to Major Depressive Disorder Relapse
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063643 · Cited by 60 · see citing works
Pharmacotherapy of depressive disorders
Centres, W. M. H. C. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90043-8 · Cited by 55 · see citing works
Treatment Approaches to Major Depressive Disorder Relapse
Fava, M., Schmidt, M. E., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063644 · Cited by 44 · see citing works
Flagged first, then by citations
2 of the 28 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372 · see citing works
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · see citing works
Kaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0910 · Cited by 135 · see citing works
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136 · see citing works
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
David, P., Wang, F., Mallinckrodt, C. H., Walker, D. J., & Detke, M. J. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.03.004 · Cited by 128 · see citing works
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107 · see citing works
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103 · see citing works
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93 · see citing works
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100 · see citing works
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
Rodrígues-Amorím, D., Olivares, J. M., Spuch, C., & Baltanás, T. R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.554899 · Cited by 99 · see citing works
Maund, E., Tendal, B., Hróbjartsson, A., Jørgensen, K. J., Lundh, A., Schroll, J. B., & Gøtzsche, P. C. (2014) · BMJ · doi:10.1136/bmj.g3510 · Cited by 89 · see citing works
Girardi, P., Pompili, M., Innamorati, M., Mancini, M., Serafini, G., Mazzarini, L., CASALE, A. D., Tatarelli, R., & Baldessarini, R. J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1005 · Cited by 86 · see citing works
Frampton, J. E., & Plosker, G. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721070-00004 · Cited by 77 · see citing works
Relapse rates with long‐term antidepressant drug therapy: a meta‐analysis
Williams, N., Simpson, A. N., Simpson, K., & Nahas, Z. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1033 · Cited by 74 · see citing works
Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder
Amsterdam, J. D., & Bodkin, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239794.37073.70 · Cited by 72 · see citing works
Wexler, T., Gunnell, L., Omer, Z., Kuhlthau, K., Beauregard, C., Graham, G., Utz, A. L., Biller, B., Nachtigall, L., Loeffler, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2671 · Cited by 69 · see citing works
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30038-x · Cited by 67 · see citing works
Miller, K. K., Wexler, T., Fazeli, P., Gunnell, L., Graham, G. J., Beauregard, C., Hemphill, L., Nachtigall, L., Loeffler, J., Swearingen, B., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1611 · Cited by 66 · see citing works
Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54 · see citing works
Self-citationA Case Study of Salami Slicing: Pooled Analyses of Duloxetine for Depression
Spielmans, G. I., Biehn, T. L., & Sawrey, D. L. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000270917 · Cited by 48 · see citing works
Effects of the Antidepressant Duloxetine on Body Weight
Wise, T. N., David, P., Pangallo, B. A., Losin, W. G., & Wiltse, C. G. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0503 · Cited by 48 · see citing works
Gardarsdottir, H., Egberts, T. C., Stolker, J. J., & Heerdink, E. R. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp142 · Cited by 47 · see citing works
Benasi, G., Fava, G. A., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506110 · Cited by 46 · see citing works
Limitations of contemporary antidepressants: tolerability.
Papakostas, G. I. (2007) · PubMed · Cited by 39 · see citing works
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38 · see citing works
Wohlreich, M. M., Mallinckrodt, C. H., Prakash, A., Watkin, J. G., & Carter, W. P. (2006) · Depression and Anxiety · doi:10.1002/da.20209 · Cited by 36 · see citing works
Maintenance study for adolescent depression
Cheung, A., Kusumakar, V., Kutcher, S., Dubo, E., Garland, J., Weiss, M., Kiss, A., & Levitt, A. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0001 · Cited by 44 · see citing works
Duloxetine in the treatment of major depressive disorder: an open-label study
Hudson, J. I., David, P., Gilaberte, I., Wang, F., Watkin, J. G., & Detke, M. J. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-43 · Cited by 34 · see citing works
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33 · see citing works
Long-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review
Furukawa, T. A., Cipriani, A., Barbui, C., & Geddes, J. R. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200902 · Cited by 33 · see citing works
Duloxetine in the treatment of major depressive disorder
GOLDSTEIN, D. J. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.193 · Cited by 33 · see citing works
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat
Cookson, J., Gilaberte, I., Desaiah, D., & Kajdasz, D. K. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00004 · Cited by 29 · see citing works
Thase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 27 · see citing works
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder
D, M. F. M., Wiltse, C. G., Walker, D. J., Brecht, S., Chen, A., & David, P. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.023 · Cited by 27 · see citing works
Duloxetine: a new selective and dual-acting antidepressant
Bauer, M., Möller, H., & Schneider, E. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.421 · Cited by 27 · see citing works
Individual residual symptoms and functional impairment in patients with depression
Romera, I., Pérez, V., Quail, D., Berggren, L., Lenox‐Smith, A., & Gilaberte, I. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.042 · Cited by 24 · see citing works
Quality of Life Measurement in Antidepressant Trials
Fruyt, J. D., & Demyttenaere, K. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000214442 · Cited by 24 · see citing works
Englisch, S., Knopf, U., Scharnholz, B., Kuwilsky, A., Deuschle, M., & Zink, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093586 · Cited by 24 · see citing works
Frank, E., Cassano, G. B., Rucci, P., Fagiolini, A. M., Maggi, L., KRAEMER, H. C., Kupfer, D. J., Pollock, B. G., Bies, R. R., Nimgaonkar, V. L., et al. (2008) · Clinical Trials · doi:10.1177/1740774508091965 · Cited by 23 · see citing works
Ball, S. G., Desaiah, D., Zhang, Q., Thase, M., & David, P. (2013) · Drugs in Context · doi:10.7573/dic.212245 · Cited by 23 · see citing works
Wiesinger, T., Kremer, S., Bschor, T., & Baethge, C. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13541 · Cited by 23 · see citing works
Norepinephrine Reuptake Inhibitors for Depression, ADHD and Other Neuropsychiatric Disorders
Maiti, S. N., & Babu, R. P. K. (2006) · Heterocycles · doi:10.3987/rev-06-sr(o)1 · Cited by 22 · see citing works
Desvenlafaxine for the treatment of major depressive disorder
Kornstein, S. G., McIntyre, R. S., Thase, M. E., & Boucher, M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.923403 · Cited by 20 · see citing works
Ma, K., Yu, J., Shao, W., Xu, X., Zhang, Z., & Zhang, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.11.018 · Cited by 20 · see citing works
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 19 · see citing works
David, P., Quail, D., Gandhi, P., Walker, D. J., & Peveler, R. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.08.023 · Cited by 18 · see citing works
Use of effect size to determine optimal dose of duloxetine in major depressive disorder
Pritchett, Y., Marciniak, M. D., Corey‐Lisle, P. K., Berzon, R. A., Desaiah, D., & Detke, M. J. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.06.013 · Cited by 18 · see citing works
Mallinckrodt, C. H., Chuang‐Stein, C., McSorley, P., Schwartz, J. H., Archibald, D., David, P., Detke, M. J., & Alphs, L. D. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.234 · Cited by 18 · see citing works
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Norman, T. R. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s4358 · Cited by 16 · see citing works
Volonteri, L. S., Colasanti, A., Cerveri, G., Fiorentini, A., Gaspari, I. D., Mauri, M. C., Valli, A., Papa, P., & Mencacci, C. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109104863 · Cited by 15 · see citing works
Zhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 13 · see citing works
Singh, M. K., & Thase, M. E. (2025) · CNS Spectrums · doi:10.1017/s1092852925000094 · Cited by 12 · see citing works
Arano, I., Sugimoto, T., Hamasaki, T., & Ohno, Y. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-33 · Cited by 12 · see citing works
Durgam, S., Chen, C., Migliore, R., Prakash, C., & Thase, M. E. (2019) · Depression and Anxiety · doi:10.1002/da.22872 · Cited by 11 · see citing works
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D. J., & David, P. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11 · see citing works
Murthy, M. K. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.08.009 · Cited by 10 · see citing works
Is there a place for ▼duloxetine?
(2007) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2007.45429 · Cited by 10 · see citing works
Boyer, P., Vialet, C., Hwang, E., & Tourian, K. A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01711 · Cited by 8 · see citing works
Nanclares, C., Gameiro‐Ros, I., Méndez‐López, I., Martínez‐Ramírez, C., Padín, J. F., Colmena, I., Baraibar, A. M., Gandı́a, L., & Garcı́a, A. G. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250969 · Cited by 8 · see citing works
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8 · see citing works
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 7 · see citing works
Review of Duloxetine and Venlafaxine in Depression
Zerjav-Lacombe, S., Tse, G., & Scott, M. J. W. (2009) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/1913-701x-142.3.144 · Cited by 6 · see citing works
Alev, L., Lenox‐Smith, A., Altın, M., & Dueñas, H. (2013) · Open Journal of Depression · doi:10.4236/ojd.2013.24011 · Cited by 5 · see citing works
Shi, N., Cao, Z., Durden, E., Schacht, A., Torres, A., & Happich, M. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.672941 · Cited by 5 · see citing works
Duloxetine : A Dual Action Antidepressant
Patel, D., S, D. S., Patel, C. G., & Singh, S. (2011) · Indo Global Journal of Pharmaceutical Sciences · doi:10.35652/igjps.2011.07 · Cited by 5 · see citing works
Pharmacological Treatment of Major Depressive Disorder: A Review
Papakostas, G. I., Bech, P., & D, M. F. M. (2009) · doi:10.1002/9780470745892.ch2 · Cited by 4 · see citing works
Jacobsen, P. L., Zhong, W., Xu, R., & Nomikos, G. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.090 · Cited by 3 · see citing works
Pan, Z., Zhang, H., Li, B., Huang, Z., Hu, Y., Chen, J., Lam, R. W. M., & Fang, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119460 · Cited by 2 · see citing works
Wojtera, M., & Sobów, T. (2018) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2018.0010 · Cited by 2 · see citing works
Pharmacotherapy of Major Depressive Disorder: Focus on Duloxetine
Muneoka, K. T. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1988 · Cited by 3 · see citing works
Síntomas residuales en el anciano con depresión
Galván, P., Fernández, E., & Fonseca, J. A. (2012) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2011.08.006 · Cited by 2 · see citing works
Dursun, S. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900028261 · Cited by 1 · see citing works
Duloxetine in the treatment of major depression and other psychiatric disorders
Blanco, C., Okuda, M., Rosenthal, H., & Lewis‐Fernández, R. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.195 · Cited by 1 · see citing works
Duloxetine in the acute and continuation treatment of major depressive disorder
Bochsler, L., Olver, J. S., & Norman, T. R. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.133 · Cited by 1 · see citing works
Tarolla, E., Brugnoli, R., & Pancheri, P. (2007) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 1 · see citing works
Cheon, E., Lee, J. Y., Choi, J.-H., Lee, Y.-J., & Koo, B. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.4.447 · Cited by 1 · see citing works
Duloxetine: pharmacologic characteristics and clinical use
Sobów, T. (2015) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2015.0029
Chapter 20. Duloxetine, Milnacipran, and Levomilnacipran
Jha, M. K., Mayes, T. L., & Trivedi, M. H. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as20 · Cited by 1 · see citing works
Management of major depressive disorder in primary care.
Dantz, B. (2008) · PubMed · Cited by 1 · see citing works
BOLAND, R. J., Gaud, K. G., & Keller, M. B. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch103 · Cited by 1 · see citing works
Pharmacotherapy of Fibromyalgia: Focus on Duloxetine
Serra, E., & Andréjak, M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1162
McIntyre, R. S., Fayyad, R. S., Guico‐Pabia, C. J., & Boucher, M. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01681
Sah, R. K., Rehan, H. S., Unni, K. E. S., Chopra, D., Manak, S., & Narula, P. K. (2010) · Health · doi:10.4236/health.2010.26093
Duloxetina: dos años y medio de experiencia
Segura, Á., Gonzalez, L. E., de Uriarte, L. G. O., Etxebeste, M. P., Aragüés, M., de Zárate, E. A. O., Ocejo, P. M., Echeveste, M., & Yáñez, L. P. (2009) · Dialnet (Universidad de la Rioja)
Duloxetine in the management of depression
McAllister-Williams, H. (2006) · Future Neurology · doi:10.2217/14796708.1.6.713
Symptom trajectories in discontinuation trials
Browning, M. D. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30054-8
Yang, H., & Papakostas, G. I. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_378-2
Yang, H., & Papakostas, G. I. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_378
Duloxetine for prevention of MDD relapse
&NA; (2006) · Inpharma Weekly · doi:10.2165/00128413-200615400-00038
(2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.3.64
Yang, H., & Papakostas, G. I. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_378
(2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.4.92
Grygorcewicz, O., Czachorowska, M., Szweda, F., Poczwardowski, T., Kaczmarek, A., Kowalska, K. A., Latos, J. T., Chwalczuk, M., Koneczna, M., Krystyniak, K. A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4659
- Authors
- Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J.
- Affiliations
- Eli Lilly (United States) (US)
- Imperial College London (GB)
- Universidad de Salamanca (ES)
- Harvard University (US)
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2006-04
- Volume
- 188
- Issue
- 4
- Pages
- 346-353
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2235189311
- Cited by
- 94
- References
- 28
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 1 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- duloxetine, major depressive disorder, relapse prevention, continuation treatment, serotonin-norepinephrine reuptake inhibitors, antidepressant efficacy, adverse events, quality of life, outpatients
- MeSH terms
- Duloxetine Hydrochloride, Adult, Analysis of Variance, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Thiophenes, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
